NCT05386446

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

Prospective Open Controlled Non-interventional Study of the Use of the Drug Ingaron (Interferon Gamma Human Recombinant, NPP Farmaklon LLC, Russia) in Volunteers for the Prevention of Coronavirus Infection COVID-19

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: SPP Pharmaclon Ltd. · Industry
• Sex: All
• Age: 21 Years – 62 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the effectiveness of the prophylactic use of Ingaron (INN: recombinant interferon gamma human, lyophilisate for solution for intranasal administration 100,000 IU) in the regimen of 3 drops in each nasal passage intranasally every other day for 10 days with a break of 7 days (2 10-day cycles) in volunteers.

Detailed description

Distribution between groups is made randomly at the request of the participant. According to the methodology approved by the observational program, the participant must use or not use the investigational drug (depending on the distribution group and their own will) during the 27 days of the prophylaxis course (10 days + 7 days + 10 days). The control group does not receive study therapy.

Conditions

• COVID-19 Respiratory Infection

Interventions

Type	Name	Description
DRUG	Interferon gamma human recombinant (IFN-G)	nasal form

Timeline

• Start date: 2020-04-23
• Primary completion: 2020-06-10
• Completion: 2020-06-15
• First posted: 2022-05-23
• Last updated: 2022-05-23

Locations

1 site across 1 country: Russia